Partial
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Many claims are generic consequences of stopping pancreatic enzyme replacement, but the provided CREON label excerpts do not support specific statements about effects occurring after stopping (e.g., rapid symptom return, stool changes within days, urgent need for care based on those specific outcomes). The response also includes several broader extrapolations (vitamin deficiency contributing to fatigue/bone/vision issues) that are not supported in the supplied label text.
Category Scores
Accurate Statements
Creon (pancrelipase) is intended to treat exocrine pancreatic insufficiency.
Supported by label Section 1: “CREON is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients.”
Unsupported Statements
If pancreatic insufficiency is still present, stopping Creon can lead to symptoms returning because food is not digested as well.
No label excerpt provided describes consequences of stopping CREON or symptom recurrence timing/mechanism after discontinuation.
Stopping Creon while still needing enzyme replacement can cause greasy, foul-smelling stools (steatorrhea) and diarrhea.
Label excerpts do not discuss effects specifically after stopping CREON; they discuss dosing/titration based on steatorrhea as a symptom for dose individualization, but not discontinuation outcomes.
Stopping Creon can cause gas, bloating, and abdominal discomfort.
Not supported by the provided label excerpts as an outcome of stopping.
Stopping Creon can lead to weight loss or trouble maintaining weight because fewer calories are absorbed.
Not supported by the provided label excerpts as an outcome of stopping.
Stopping Creon can lead to nutrient deficiencies over time, including deficiencies of fat-soluble vitamins A, D, E, and K.
The provided label excerpts do not mention vitamin deficiencies resulting from stopping CREON.
Digestive symptoms can return quickly once enzyme coverage stops.
No label excerpt provided addresses “quickly” or timing of symptom return after discontinuation.
In many cases, stool changes and bloating can show up within days after stopping Creon.
No label excerpt provided supports timing statements about symptom appearance after stopping.
If pancreatic enzyme replacement is truly needed, stopping Creon can lead to ongoing diarrhea and fatty stools.
Not described in the provided label excerpts as a discontinuation effect.
If pancreatic enzyme replacement is truly needed, stopping Creon can lead to progressive weight loss and worsening nutrition.
Not described in the provided label excerpts as a discontinuation effect.
Stopping Creon can cause deficiencies of fat-soluble vitamins.
Not supported by provided label excerpts.
Fat-soluble vitamin deficiencies can contribute to fatigue.
No such causal or association statements are present in the provided label excerpts.
Fat-soluble vitamin deficiencies can contribute to bone issues.
No such statements are present in the provided label excerpts.
Fat-soluble vitamin deficiencies can contribute to vision changes.
The label excerpt includes postmarketing “Eye disorders: blurred vision” but does not link vitamin deficiencies from stopping to vision changes.
Creon-related allergic reactions are uncommon.
The provided label excerpts do not state frequency of hypersensitivity reactions as “uncommon.” (They state hypersensitivity reactions have been reported.)
If Creon is stopped, new allergic-type symptoms would generally not be expected because the drug is not being taken.
No label excerpt supports this general statement about hypersensitivity symptom expectations after stopping.
Hives, swelling, or breathing problems after stopping any medication should be treated as urgent and investigated promptly.
The label excerpt advises monitoring and describes severe hypersensitivity reactions including anaphylaxis and hives, but does not provide the specific “after stopping any medication” urgent-treatment instruction.
Stopping Creon that leads to severe or persistent diarrhea can require medical care quickly.
Not supported by the provided label excerpts as a specific discontinuation guidance.
Stopping Creon that leads to significant weight loss can require medical care quickly.
Not supported by the provided label excerpts as a discontinuation guidance.
Stopping Creon with signs of dehydration can require medical care quickly.
Not supported by the provided label excerpts.
Stopping Creon with blood in stool can require medical care quickly.
Not supported by the provided label excerpts.
Stopping Creon with symptoms of vitamin deficiency can require medical care quickly.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
No discussion of label-supported hypersensitivity/clinical safety monitoring details beyond generic assertions (e.g., severe hypersensitivity reactions including anaphylaxis, asthma, hives, and pruritus have been reported; monitor patients with known hypersensitivity).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are not supported by the provided CREON label excerpts, particularly those asserting specific outcomes and timing after stopping CREON, and urgent-care recommendations based on symptoms (blood in stool, dehydration, vitamin deficiency). The label excerpts do support that hypersensitivity reactions can occur and that high dosing may be associated with fibrosing colonopathy, but the response focuses on discontinuation consequences not covered in the provided text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Not Aligned
Primary Issue
Many discontinuation/timing and nutrient-deficiency consequence claims are unsupported by the provided FDA label excerpts; several include speculative causal links and specific urgency guidance not present in the label text supplied.
Suggested Improvement
Restrict claims to label-supported information from Sections 1, 2.1–2.3, 5 (including hypersensitivity and fibrosing colonopathy) and 6 (adverse reactions). Remove or qualify statements about effects specifically after stopping CREON and remove unsupported associations (fatigue/bone/vision issues) unless supported by label text.